ConductScience.org, home

Paper36298564

The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.

Tian D and 3 others. Vaccines (Basel), 2022. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection. Papers, record 36298564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36298564

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.
PubMed
Journal
Vaccines (Basel)
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.89
iCite
Revised in PubMed
2023-11-06
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tian DDandan
2Nie WWenjian
3Sun YYanhong
4Ye QQing

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135474907SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants.Comput Struct Biotechnol J2022https://conductscience.org/library/papers/35474907PubMed
234166623Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.Immunity2021https://conductscience.org/library/papers/34166623PubMed
335871089In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.Sci Rep2022https://conductscience.org/library/papers/35871089PubMed
433735608SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.Cell2021https://conductscience.org/library/papers/33735608PubMed
532571838A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.Science2020https://conductscience.org/library/papers/32571838PubMed
634754982Analysis of SARS-COV2 spike protein variants among Iraqi isolates.Gene Rep2022https://conductscience.org/library/papers/34754982PubMed
736436752Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.Int J Infect Dis2023https://conductscience.org/library/papers/36436752PubMed
835714668BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.Nature2022https://conductscience.org/library/papers/35714668PubMed
935853878Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35853878PubMed
1033853970Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.Science2021https://conductscience.org/library/papers/33853970PubMed
1135750920What Omicron's BA.4 and BA.5 variants mean for the pandemic.Nature2022https://conductscience.org/library/papers/35750920PubMed
1236379191Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants.Comput Biol Med2022https://conductscience.org/library/papers/36379191PubMed
1335731894Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.N Engl J Med2022https://conductscience.org/library/papers/35731894PubMed
1435484110SARS-CoV-2 Omicron variant: recent progress and future perspectives.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35484110PubMed
1535118687The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant.J Med Virol2022https://conductscience.org/library/papers/35118687PubMed
1635264324Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.BMJ2022https://conductscience.org/library/papers/35264324PubMed
1735690075Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.Lancet Infect Dis2022https://conductscience.org/library/papers/35690075PubMed
1835772405Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.Cell2022https://conductscience.org/library/papers/35772405PubMed
1935777385Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.Lancet Infect Dis2022https://conductscience.org/library/papers/35777385PubMed
2035770368The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend.J Med Virol2022https://conductscience.org/library/papers/35770368PubMed

See all 48 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42079734Genomic insights into SARS-CoV-2 evolution in Yantai, China after the adjustment of the dynamic zero-COVID policy in 2023.PeerJ2026https://conductscience.org/library/papers/42079734PubMed
40369416In-depth analysis of the risk factors for persistent severe acute respiratory syndrome coronavirus 2 infection and construction of predictive models: an exploratory research study.BMC Infect Dis2025https://conductscience.org/library/papers/40369416PubMed
39443934Oral complications during the two waves of COVID-19 pandemic in China: a prospective cross-section analysis of 510 cases using questionnaire.BMC Oral Health2024https://conductscience.org/library/papers/39443934PubMed
38587722Analysis of SARS-CoV-2 omicron mutations that emerged during long-term replication in a lung cancer xenograft mouse model.Virus Genes2024https://conductscience.org/library/papers/38587722PubMed
38263035The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao.Chin Med2024https://conductscience.org/library/papers/38263035PubMed
38257736Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives.Viruses2023https://conductscience.org/library/papers/38257736PubMed
38169898Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study.Heliyon2024https://conductscience.org/library/papers/38169898PubMed
38156316An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.Front Cell Infect Microbiol2023https://conductscience.org/library/papers/38156316PubMed
38003257Comparative Computational Analysis of Spike Protein Structural Stability in SARS-CoV-2 Omicron Subvariants.Int J Mol Sci2023https://conductscience.org/library/papers/38003257PubMed
37954618SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.Front Immunol2023https://conductscience.org/library/papers/37954618PubMed
37645409Clinical characteristics and acute complication of COVID-19 patients with diabetes: a multicenter, retrospective study in Southern China.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37645409PubMed
37553605Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study.BMC Gastroenterol2023https://conductscience.org/library/papers/37553605PubMed
37444682One Pandemic, Two Solutions: Comparing the U.S.-China Response and Health Priorities to COVID-19 from the Perspective of "Two Types of Control".Healthcare (Basel)2023https://conductscience.org/library/papers/37444682PubMed
37243100Association between Overweight/Obesity and the Safety and Efficacy of COVID-19 Vaccination: A Systematic Review.Vaccines (Basel)2023https://conductscience.org/library/papers/37243100PubMed
36851526Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity.Viruses2023https://conductscience.org/library/papers/36851526PubMed
36704960Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.Hum Vaccin Immunother2023https://conductscience.org/library/papers/36704960PubMed
36641977Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study.Phytomedicine2023https://conductscience.org/library/papers/36641977PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACE259272PubTator's text mininghttps://conductscience.org/library/genes/59272NCBI Gene
TMED210959PubTator's text mininghttps://conductscience.org/library/genes/10959NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36298564

GET https://conductscience.org/api/papers/v1/36298564/references?page=2